Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1978 Feb;62(2):213–218. doi: 10.1111/j.1476-5381.1978.tb08448.x

Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol.

L Ahtee, S Kaakkola
PMCID: PMC1667802  PMID: 564219

Abstract

1 The effects of the nicotinic cholinoceptor blocking drug, mecamylamine (alone or in combination with morphine or haloperidol) were investigated on the striatal homovanillic acid (HVA) concentration and on the alpha-methyl-p-tyrosine (AMPT)-induced depletion of striatal or mesolimbic dopamine content in the brain of rats. 2 Mecamylamine (2 mg/kg) alone did not alter the striatal HVA concentration, but it reduced the probenecid-induced accumulation of HVA. Mecamylamine pretreatment reduced the morphine- and haloperidol-induced elevation of striatal HVA concentrations. Hexamethonium did not alter the striatal HVA concentration when given alone or in probenecid- or morphine-treated rats, whereas pempidine (8 mg/kg) clearly reduced the probenecid-induced accumulation of HVA in the striatum. 3 Mecamylamine (2 and 8 mg/kg) slowed the rate of AMPT-induced depletion of dopamine from the striatum and mesolimbic area both in the brain of control rats treated with morphine or haloperidol. 4 Mecamylamine slightly prolonged the cataleptic effect of morphine. 5 The results indicate that mecamylamine inhibits the release of dopamine both from the striatal and mesolimbic dopaminergic neurones.

Full text

PDF
213

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahtee L. Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone. Eur J Pharmacol. 1976 Oct;39(2):203–213. doi: 10.1016/0014-2999(76)90128-x. [DOI] [PubMed] [Google Scholar]
  2. Bartholini G., Pletscher A. Atropine-induced changes of cerebral dopamine turnover. Experientia. 1971;27(11):1302–1303. doi: 10.1007/BF02136701. [DOI] [PubMed] [Google Scholar]
  3. Beleslin D. B., Malobabić Z. S. Catalepsy produced by intraventricular injection of nicotine. Experientia. 1972 Apr 15;28(4):427–428. doi: 10.1007/BF02008320. [DOI] [PubMed] [Google Scholar]
  4. Carlsson A., Kehr W., Lindqvist M. Agonist--antagonist interaction on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation. J Neural Transm. 1977;40(2):99–113. doi: 10.1007/BF01250562. [DOI] [PubMed] [Google Scholar]
  5. Cashin C. H., Sutton S. The effect of anti-Parkinson drugs on catalepsy induced by -methyl-p-tyrosine in rats pretreated with intraventricular 6-hydroxydopamine. Br J Pharmacol. 1973 Mar;47(3):658P–659P. [PMC free article] [PubMed] [Google Scholar]
  6. Costall B., Naylor R. J. Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforschung. 1973 May;23(5):674–683. [PubMed] [Google Scholar]
  7. Giorguieff M. F., Le Floc'h M. L., Westfall T. C., Glowinski J., Besson M. J. Nicotinic effect of acetylcholine on the release of newly synthesized (3H)dopamine in rat striatal slices and cat caudate nucleus. Brain Res. 1976 Apr 16;106(1):117–131. doi: 10.1016/0006-8993(76)90077-9. [DOI] [PubMed] [Google Scholar]
  8. Haubrich D. R., Goldberg M. E. Homovanillic acid concentration in rat brain: effect of a choline acetyltransferase inhibitor and comparison with cholinergic and dopaminergic agents. Neuropharmacology. 1975 Mar;14(3):211–214. doi: 10.1016/0028-3908(75)90007-6. [DOI] [PubMed] [Google Scholar]
  9. Hornykiewicz O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull. 1973 May;29(2):172–178. doi: 10.1093/oxfordjournals.bmb.a070990. [DOI] [PubMed] [Google Scholar]
  10. Kuschinsky K. Actions of narcotics on brain dopamine metabolism and their relevance for "psychomotor" effects. Arzneimittelforschung. 1976 Apr;26(4):563–567. [PubMed] [Google Scholar]
  11. O'Keeffe R., Sharman D. F., Vogt M. Effect of drugs used in psychoses on cerebral dopamine metabolism. Br J Pharmacol. 1970 Feb;38(2):287–304. doi: 10.1111/j.1476-5381.1970.tb08517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Portig P. J., Sharman D. F., Vogt M. Release by tubocurarine of dopamine and homovanillic acid from the superfused caudate nucleus. J Physiol. 1968 Feb;194(2):565–572. doi: 10.1113/jphysiol.1968.sp008425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Roos B. E. Decrease in homovanillic acid as evidence for dopamine receptor stimulation by apomorphine in the neostriatum of the rat. J Pharm Pharmacol. 1969 Apr;21(4):263–264. doi: 10.1111/j.2042-7158.1969.tb08243.x. [DOI] [PubMed] [Google Scholar]
  14. SPECTOR S., SJOERDSMA A., UDENFRIEND S. BLOCKADE OF ENDOGENOUS NOREPINEPHRINE SYNTHESIS BY ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASE. J Pharmacol Exp Ther. 1965 Jan;147:86–95. [PubMed] [Google Scholar]
  15. Sharman D. F. A discussion of the modes of action of drugs which increase the concentration of 4-hydroxy-3-methoxyphenylacetic acid (homovanillic acid) in the striatum of the mouse. Br J Pharmacol Chemother. 1967 Aug;30(3):620–626. doi: 10.1111/j.1476-5381.1967.tb02168.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shellenberger M. K., Gordon J. H. A rapid, simplified procedure for simultaneous assay of norepinephrine, dopamine, and 5-hydroxytryptamine from discrete brain areas. Anal Biochem. 1971 Feb;39(2):356–372. doi: 10.1016/0003-2697(71)90426-x. [DOI] [PubMed] [Google Scholar]
  17. Simon P., Malatray J., Boissier J. R. Antagonism by amantadine of prochlorpemazine-induced catalepsy. J Pharm Pharmacol. 1970 Jul;22(7):546–547. doi: 10.1111/j.2042-7158.1970.tb10567.x. [DOI] [PubMed] [Google Scholar]
  18. Westfall T. C. Effect of nicotine and other drugs on the release of 3H-norepinephrine and 3H-dopamine from rat brain slices. Neuropharmacology. 1974 Aug;13(8):693–700. doi: 10.1016/0028-3908(74)90015-x. [DOI] [PubMed] [Google Scholar]
  19. Zetler G. Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs. Int J Neuropharmacol. 1968 Jul;7(4):325–335. doi: 10.1016/0028-3908(68)90015-4. [DOI] [PubMed] [Google Scholar]
  20. Zetler G. Pharmacological differentiation of "nicotinic" and "muscarinic" catalepsy. Neuropharmacology. 1971 May;10(3):289–296. doi: 10.1016/0028-3908(71)90052-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES